Shi Y, Chen J, Shi B, Liu A, et al. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. Gynecol Oncol 2021 Dec 14. pii: S0090-8258(21)01633.
PMID: 34920886